Target Name: SNORD89
NCBI ID: G692205
Review Report on SNORD89 Target / Biomarker Content of Review Report on SNORD89 Target / Biomarker
SNORD89
Other Name(s): Small nucleolar RNA, C/D box 89 | small nucleolar RNA, C/D box 89 | HBII-289

SNORD89: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to help maintain the stability of the endoplasmic reticulum by binding to specific protein targets, including other snRNAs and proteins. One of the well-known snRNAs is SNORD89, which is a 22-nt RNA molecule that contains a conserved C/D box region.

The C/D box region is a common structural feature that is found in many snRNAs and is composed of a core of RNA secondary structure and a terminal region that contains a phosphate group and a variable number of nuclear glycosides. region plays a critical role in the regulation of gene expression by binding to specific protein targets, including other snRNAs and proteins.

SNORD89 is a well-known snRNA that is expressed in various tissues and cells, including brain, heart, and muscle. It is also known to play a role in the regulation of gene expression in these tissues, and is often used as a biomarker for certain diseases.

One of the potential applications of SNORD89 as a drug target is its role in the regulation of gene expression in cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells, and it is a major cause of human mortality and morbidity . Many studies have shown that the regulation of gene expression is a key factor in the development and progression of cancer, and that SNORD89 plays a critical role in this process.

SNORD89 has been shown to be involved in the regulation of gene expression in a variety of cancer types, including breast, ovarian, and colorectal cancers. For example, studies have shown that SNORD89 is expressed in various types of cancer and that it is involved in the regulation of gene expression in these cancers.

Another potential application of SNORD89 as a drug target is its role in the regulation of gene expression in neurodegenerative diseases. Neurodegenerative diseases are a group of diseases that are characterized by the progressive loss of brain cells and their associated symptoms, and they are a major cause of human disability and quality of life. Many studies have shown that the regulation of gene expression is a key factor in the development and progression of neurodegenerative diseases, and that SNORD89 plays a critical role in this process.

SNORD89 has been shown to be involved in the regulation of gene expression in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. For example, studies have shown that SNORD89 is expressed in the brains of individuals with Alzheimer's disease and that it is involved in the regulation of gene expression in these individuals.

In addition to its potential applications as a drug target and biomarker, SNORD89 is also of interest as a potential therapeutic agent. The C/D box region of SNORD89 provides a structure that could be targeted by small molecules, and studies have shown that this region is responsive to small molecules such as economically promising drug molecules.

Conclusion

SNORD89 is a well-known snRNA that is expressed in various tissues and cells, and is involved in the regulation of gene expression in a variety of processes. Its potential applications as a drug target and biomarker are its role in the regulation of gene expression in cancer and neurodegenerative diseases, as well as its structure, which could be targeted by small molecules. Further research is needed to fully understand the role of SNORD89 in these processes and to develop safe and effective therapies based on this molecule.

Protein Name: Small Nucleolar RNA, C/D Box 89

The "SNORD89 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD89 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNORD9 | SNORD90 | SNORD91A | SNORD92 | SNORD93 | SNORD94 | SNORD95 | SNORD96A | SNORD96B | SNORD97 | SNORD98 | SNORD99 | SNPH | SNRK | SNRK-AS1 | SNRNP200 | SNRNP25 | SNRNP27 | SNRNP35 | SNRNP40 | SNRNP48 | SNRNP70 | SNRPA | SNRPA1 | SNRPB | SNRPB2 | SNRPC | SNRPCP10 | SNRPCP16 | SNRPCP17 | SNRPCP3 | SNRPD1 | SNRPD2 | SNRPD3 | SNRPE | SNRPEP2 | SNRPEP4 | SNRPF | SNRPF-DT | SNRPG | SNRPGP10 | SNRPGP18 | SNRPN | SNTA1 | SNTB1 | SNTB2 | SNTG1 | SNTG2 | SNTG2-AS1 | SNTN | SNU13 | SNUPN | SNURF | SNURFL | SNW1 | SNX1 | SNX10 | SNX10-AS1 | SNX11 | SNX12 | SNX13 | SNX14 | SNX15 | SNX16 | SNX17 | SNX18 | SNX18P23 | SNX18P24 | SNX18P3 | SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT